{
    "nctId": "NCT02473120",
    "briefTitle": "Study of ESR1 Mutations in Metastatic Breast Cancer",
    "officialTitle": "Determination of ESR1 Mutations by Digital PCR During Aromatase Inhibitor Treatment in Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 104,
    "primaryOutcomeMeasure": "Frequency of ESR1 mutations",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Woman aged superior to 18 years old\n* Inform consent signed\n* Metastatic breast cancer or loco-regionnaly advanced breast cancer\n* Inoperable\n* With an indication to treat with aromatase inhibitor\n* Treatment with aromatase inhibitors innitiated at the inclusion or at least 6 months before inclusion with a stable disease\n* Without precedent treatment or with treatment by chemotherapy/tamoxifen/faslodex or aromatase inhibitors in a adjuvant treatment and with a time frame of 2 years between last treatment with aromatase inhibitors and metastatic evolution\n* Treatment by aromatase inhibitors alone or in combination with a targeted therapy (trastuzumab +/- pertuzumab, bevacizumab, everolimus)\n\nExclusion Criteria:\n\n* No inform consent signed\n* Patient under guardianship, curatorship\n* Psychosocial disorder\n* No affiliated or beneficiary of a social benefit system",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}